VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | DREAMM-2: belantamab mafodotin for R/R MM

VJHemOnc is committed to improving our service to you

Maria-Victoria Mateos

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the use of belantamab mafodotin in relapsed/refractory (R/R) multiple myeloma (MM) refractory to proteasome inhibitors, immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter